GHRS | GH Research PLC Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.72 - 7.63
52 Week Range	5.08 - 14.99
Beta	0.75
Implied Volatility	150.32%
IV Rank	76.33%
Day's Volume	76,444
Average Volume	65,585
Shares Outstanding	52,028,100
Market Cap	356,392,485
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-06-25

Valuation
Profitability
Growth
Health
P/E Ratio	-8.67
Forward P/E Ratio	N/A
EPS	-0.79
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	49
Country	Ireland
Website	GHRS

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GHRS's peers: ATAI, MOLN, MNOV, ANEB, CSBR, CYT, MLYS, ELYM, JANX, RZLT, PMVP, PHVS, PEPG, GLUE, DSGN, HOWL, IKNA, STOK, RCUS, CGEM, ANNX, GPCR, RLAY, CYBN, MNMD

*Chart delayed

Analyzing fundamentals for GHRS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see GHRS Fundamentals page.

Watching at GHRS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GHRS Technicals page.